{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"SPRINT Trial: Mortality Benefit Associated with Intensive Blood Pressure Control - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"HlYKgf5S7o\"><a href=\"https:\/\/themedicalxchange.com\/en\/2015\/11\/16\/american-heart-association-aha-scientific-sessio-5\/\">SPRINT Trial: Mortality Benefit Associated with Intensive Blood Pressure Control<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2015\/11\/16\/american-heart-association-aha-scientific-sessio-5\/embed\/#?secret=HlYKgf5S7o\" width=\"600\" height=\"338\" title=\"&#8220;SPRINT Trial: Mortality Benefit Associated with Intensive Blood Pressure Control&#8221; &#8212; The Medical Xchange\" data-secret=\"HlYKgf5S7o\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2015\/11\/2358_AHA_2015_EN_Fig_1.png","thumbnail_width":960,"thumbnail_height":720,"description":"Orlando \u2013 A new therapeutic goal in the management of hypertension has been established by a landmark trial, with highly anticipated findings presented at this year\u2019s AHA meeting. The large multicenter trial, called SPRINT, demonstrated that risk of cardiovascular (CV) events and all-cause mortality are significantly reduced in patients at increased risk if the systolic blood pressure (SBP) treatment goal is 120 mmHg. To bring patients consistently to this goal from the current guideline level of"}